Johns Hopkins School of Medicine

Quest Diagnostics Elects Luis A. Diaz, Jr., M.D. to its Board, Expanding the Number of Directors to 10

Retrieved on: 
Wednesday, May 17, 2023
DNA, Quest Diagnostics, University, Neoplasm, Biotechnology, Cancer, Research, Genomics, Immunotherapy, Bangladesh Technical Education Board, Patient, Division, Memorial Sloan Kettering Cancer Center, Johns Hopkins, FDA, NYSE, DGX, Johns Hopkins School of Medicine, Management, Pharmaceutical industry, Medical imaging

SECAUCUS, N.J., May 17, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors has elected Luis A. Diaz, Jr., M.D.

Key Points: 
  • SECAUCUS, N.J., May 17, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors has elected Luis A. Diaz, Jr., M.D.
  • Dr. Diaz, 52, has been Head of the Division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center since December 2016.
  • Previously, he was a faculty member and physician at the Johns Hopkins University School of Medicine.
  • Dr. Diaz received his undergraduate and medical degrees from the University of Michigan and completed his medical training at Johns Hopkins.

American Thoracic Society Selects Immune IQ to Present Breakthrough Point-of-Care Diagnostic Technology at the 2023 Respiratory Innovation Summit

Retrieved on: 
Wednesday, May 17, 2023
Infection, Survivor, Hospice and palliative medicine, Office of Inspector General, U.S. Department of Health and Human Services, Sepsis, Health, Human services, ATS, Immunity (medical), COVID-19, Cancer, Quality of life, Intelligence, Organ dysfunction, EST, Research, American Thoracic Society, Death, Immune system, Honeywell, Artificial intelligence, Diagnosis, Success, Anesthesiology, Disease, Johns Hopkins School of Medicine, Vaccine

Immune IQ founder and CEO, David Deetz, will present on May 20, 2023, at 11:30 am EST.

Key Points: 
  • Immune IQ founder and CEO, David Deetz, will present on May 20, 2023, at 11:30 am EST.
  • "It is an honor to have been chosen by the American Thoracic Society to present at this year's Respiratory Innovation Summit and share how Immune IQ is transforming the way we diagnose and treat a wide range of health conditions by harnessing the power of the human immune system."
  • The Immune Reveal point-of-care diagnostic platform provides diagnostic data more rapidly and cost-effectively than ever before.
  • Immune IQ is pursuing sepsis identification as the initial test to be commercialized on the Immune Reveal platform.

ASLAN Pharmaceuticals Presents New Data on Eblasakimab and Farudodstat in Two Late-Breaking Presentations at the 1st International Societies for Investigative Dermatology Meeting

Retrieved on: 
Monday, May 15, 2023
Learning, Hair, IL-12, ISID, ASLN, Research fellow, TARC, HF, DHODH, MHC, HFS, IP-10, Atopic dermatitis, Research, Inflammation, IP, Publication, Associate, Immune privilege, II, IL-2, Alopecia areata, Organization, Patient, International Society for Traumatic Stress Studies, SAN, Autoimmune disease, GM-CSF, Epithelium, MHC-II, Cytokine, AD, T helper cell, Johns Hopkins School of Medicine, Vaccine, Pharmaceutical industry, Dermatology, TH1, AA

“This late-breaking data offers new and important insights into the novel mechanisms of eblasakimab and farudodstat for atopic dermatitis (AD) and alopecia areata (AA) respectively," said Dr Ferda Cevikbas, Head of Translational Science at ASLAN Pharmaceuticals.

Key Points: 
  • “This late-breaking data offers new and important insights into the novel mechanisms of eblasakimab and farudodstat for atopic dermatitis (AD) and alopecia areata (AA) respectively," said Dr Ferda Cevikbas, Head of Translational Science at ASLAN Pharmaceuticals.
  • “Furthermore, data from an ex vivo human AA disease model demonstrates the potential for farudodstat to protect against immune privilege collapse in AA.
  • This study investigated whether farudodstat, a DHODH inhibitor, has potential in the treatment of AA using an innovative ex vivo model for AA.
  • Together, the findings highlight the potential for farudodstat as a novel therapy for AA.

Deep Bio's AI Algorithm Helps Risk Stratification for Prostate Cancer

Retrieved on: 
Thursday, May 11, 2023
ISUP, Gleason, Marie Cassidy, AUA, American Urological Association, Prognosis, Research, Johns Hopkins School of Medicine, Patient, Algorithm, Diagnosis, AI, Recurrence, Prostate cancer, Software, Medical device, Medical imaging

SEOUL, South Korea, May 11, 2023 /PRNewswire-PRWeb/ -- Deep Bio, a pioneer in medical AI for digital pathology and cancer diagnostics support software, announced that Dr. Lotan from Johns Hopkins Medicine presented their collaborative research which utilized the deep learning-based algorithm for prostate cancer diagnosis support at a podium session in the American Urological Association (AUA) annual meeting 2023.

Key Points: 
  • This joint research compared human pathologists and an AI algorithm in grading prostate biopsy specimens to predict biochemical recurrence after radical prostatectomy.
  • Gleason score is one of the key elements to grade prostate cancer and can lead to different clinical decisions.
  • To compare human pathologists and AI algorithms, Deep Bio's AI-based prostate cancer diagnosis support software DeepDx® Prostate analyzed all the biopsies to provide Gleason grades as well.
  • This risk stratification has the potential to prevent a lot of unnecessary surgeries and aid in choosing between treatment modalities.

Vivante Adds Prominent Gastroenterology Specialists to Clinical Advisory Board

Retrieved on: 
Monday, May 8, 2023
Gastrointestinal cancer, Vivante Corporation, Gastroenterology, Epidemiology, Biotechnology, Columbia University Irving Medical Center, Health, David Geffen School of Medicine at UCLA, Quality of life, DRS, Johns Hopkins School of Medicine, Research, Irritable bowel syndrome, National Cancer Institute, Physician, IBS, Stanford University Medical Center, Machine learning, Colorectal cancer, Drug discovery, Diagnosis, Growth, UCLA, Herbert, Pharmaceutical industry, Nursing, Medicine

CHICAGO, May 8, 2023  /PRNewswire/ -- Vivante Health, the leading provider of digital digestive health solutions for employers and health plans, today announced the addition of Dr. Chin Hur and Dr. Uri Ladabaum to the company's clinical advisory board. Both physicians hold professorships at top university medical centers and have conducted extensive research into gastrointestinal diseases.

Key Points: 
  • CHICAGO, May 8, 2023 /PRNewswire/ -- Vivante Health , the leading provider of digital digestive health solutions for employers and health plans, today announced the addition of Dr. Chin Hur and Dr. Uri Ladabaum to the company's clinical advisory board.
  • Both join Vivante's clinical advisory board at a time when the company is preparing to launch industry-first enhancements to its GIThrive digital digestive health platform.
  • Hur and Ladabuam are nationally recognized clinical and research leaders in gastroenterology who are at the forefront of innovation in the field.
  • "I look forward to working with them and our entire clinical advisory board so we can continue to provide the highest quality care for the members we serve."

Panbela Provides Business Update and Reports Q1 2023 Financial Results

Retrieved on: 
Thursday, May 4, 2023
Pancreatic cancer, JDRF, Abstract, AACR, Therapy, MSN, Eflornithine, American Association for Cancer Research, PBLA, Research, Doctor of Philosophy, IDS, EMA, Indiana University School of Medicine, CPP, Acquisition, Patent, Patient, DFMO, Endocrine Society, Immunology, Ovarian cancer, Johns Hopkins School of Medicine, Pharmaceutical industry, Life insurance

MINNEAPOLIS, May 04, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended March 31, 2023.

Key Points: 
  • MINNEAPOLIS, May 04, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended March 31, 2023.
  • Poster presentation highlighting the results for ivospemin (SBP-101) as a polyamine metabolism modulator in ovarian cancer at the American Association for Cancer Research (AACR), which took place April 14-19, 2023.
  • Announced the first patient enrolled in a Phase II double-blind, randomized study to evaluate CPP-1X-T (eflornithine tablets) for recent onset type 1 diabetes.
  • Research and development expenses were $3.5 million in the first quarter of 2023, compared to $2.2 million in the first quarter of 2022.

Nusano to Host Key Opinion Leader Webinar on Isotope Production and Applications for Oncology Radiopharmaceuticals

Retrieved on: 
Thursday, May 4, 2023
Radiology, Functional, University of New Mexico, KOL, Society, Birmingham School of Law, University, Radionuclide, PSMA, Molecular imaging, Society of Nuclear Medicine and Molecular Imaging, Radiation, Cancer, National Cancer Institute, EST, Los Alamos National Laboratory, MBA, Research, Nuclear medicine, Radiopharmaceutical, Doctor of Philosophy, Radiation therapy, Associate, Harvard Medical School, DSM-IV codes, Johns Hopkins School of Medicine, Publication, MD, Peptide, Argonne National Laboratory, Central nervous system disease, Diagnosis, Birmingham, Health, Prostate cancer, Medical imaging, Pharmacy, Medicine

They will discuss the technical aspects of isotope production and provide a clinical overview of the therapeutic applications of radioisotopes in oncology.

Key Points: 
  • They will discuss the technical aspects of isotope production and provide a clinical overview of the therapeutic applications of radioisotopes in oncology.
  • Nusano management will also discuss how the company is poised to dramatically increase rare isotope supplies and how its proprietary particle beam technology is the first significant advancement in radioisotope production in decades.
  • He began his research as a doctoral student at Argonne National Laboratory investigating the production of radioisotopes for medical applications.
  • He returned to Argonne to lead the nuclear medicine research group with a concurrent appointment in the Radiation Oncology Dept.

GlycoEra AG Expands Board of Directors and Appoints Santiago Arroyo, MD to its Board of Directors as an independent board member

Retrieved on: 
Tuesday, May 2, 2023
Momenta, Therapy, Pfizer, Medical college, Clifton Springs Hospital & Clinic, Biotechnology, Bristol Myers Squibb, Bicycle, Associate, Universidad, Acquisition, MD, Patient, Medical College of Wisconsin, Knowledge, Johnson & Johnson, Johns Hopkins School of Medicine, Pharmaceutical industry, Management, Lundbeck

Dr. Arroyo is a tenured pharmaceutical executive who has deep expertise in strategy and leading the clinical development of therapeutics across multiple disease areas.

Key Points: 
  • Dr. Arroyo is a tenured pharmaceutical executive who has deep expertise in strategy and leading the clinical development of therapeutics across multiple disease areas.
  • Prior to joining Bicycle, Dr. Arroyo held the Chief Medical Officer position at Momenta Pharmaceuticals, leading the company's clinical development programs until Momenta's acquisition by Johnson & Johnson.
  • We look forward to working closely with him and benefiting from his strategic insights and deep leadership and operational expertise."
  • I look forward to working together with the highly experienced Board and leadership team to build GlycoEra into a leading protein degradation company" said Dr. Santiago Arroyo.

TULSA Procedure Featured in the Scientific Program at the American Urological Association 2023 Annual Meeting

Retrieved on: 
Monday, May 1, 2023
Prostate cancer, Comparison, McCormick Place, BPH, AUA, LUTS, Clinical trial, Cancer, American Urological Association, Prostate, Patient, United States Army Medical Corps, Annual general meeting, Fellow, Pivotal, TSX, University of Oslo, Prostatectomy, Erectile dysfunction, Safety, Level 1, Johns Hopkins School of Medicine, Pharmaceutical industry, Medical imaging

TORONTO, May 01, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced the presentation of four studies of the Transurethral Ultrasound Ablation (“TULSA”) procedure at the American Urological Association (“AUA”) 2023 Annual Meeting, which took place from April 28 - May 1, 2023 at McCormick Place in Chicago, Illinois.

Key Points: 
  • The data demonstrate that both oncological control and functional outcomes are durable to four years after treatment with TULSA.
  • Urinary function was durable over the four-year follow-up period, with 99% of patients preserving urinary continence (≤1 pad/day) and 94% remaining completely pad-free.
  • At follow-up, oncological success was 88%, with 85% of men with LUTS before treatment experiencing relief after treatment with TULSA.
  • There were two Grade 4 complications - one after HIFU ablation and one after RALP - but none after TULSA.

IN8bio Appoints Jeremy Graff, Ph.D., to Board of Directors

Retrieved on: 
Monday, May 1, 2023
Science, Drug development, Parliamentary Information Technology Committee, Biotechnology, Cancer, United States Air Force Scientific Advisory Board, Eli Lilly, Patient, Trustee, Knowledge, Eli Lilly and Company, Johns Hopkins School of Medicine, Pharmaceutical industry

“Dr.

Key Points: 
  • “Dr.
  • “Dr.
  • This group supported and advanced the 31 clinical assets in Eli Lilly’s oncology portfolio at the time.
  • He completed a post-doctoral fellowship at the Johns Hopkins University School of Medicine.